<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">phkinetica</journal-id><journal-title-group><journal-title xml:lang="ru">Фармакокинетика и Фармакодинамика</journal-title><trans-title-group xml:lang="en"><trans-title>Pharmacokinetics and Pharmacodynamics</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2587-7836</issn><issn pub-type="epub">2686-8830</issn><publisher><publisher-name>ООО «Издательство ОКИ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37489/2587-7836-2024-2-50-56</article-id><article-id custom-type="edn" pub-id-type="custom">YJKWFL</article-id><article-id custom-type="elpub" pub-id-type="custom">phkinetica-419</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ДОКЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ ФАРМАКОДИНАМИКИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PRECLINICAL PHARMACODYNAMICS STUDIES</subject></subj-group></article-categories><title-group><article-title>Экспериментальная модель расстройств аутистического спектра, вызванная пренатальным введением пропионовой кислоты крысам Вистар</article-title><trans-title-group xml:lang="en"><trans-title>Experimental model of autism spectrum disorder induced by prenatal administration of propionic acid to Wistar rats</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8167-0406</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бояркин</surname><given-names>В. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Boyarkin</surname><given-names>V. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бояркин Валентин Сергеевич, аспирант, м. н. с. лаборатории фармакологии психических заболеваний, отдела нейропсихофармакологии</p><p>Москва</p></bio><bio xml:lang="en"><p>Valentin S. Boyarkin, Postgraduate student, Junior Researcher at the, Laboratory of Pharmacology of Mental Diseases, Department of Neuropsychopharmacology</p><p>Moscow</p></bio><email xlink:type="simple">bojarkin_vs@academpharm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4487-0991</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Капица</surname><given-names>И. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Kapitsa</surname><given-names>I. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Капица Инга Геннадиевна, к. б. н., в. н. с., начальник отдела интеллектуальной собственности</p><p>Москва</p></bio><bio xml:lang="en"><p>Inga G. Kapitsa, PhD, Cand. Sci. (Biology), Leading Researcher, Head of the Intellectual Property Department</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7065-469X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Воронина</surname><given-names>Т. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Voronina</surname><given-names>T. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Воронина Татьяна Александровна, д. м. н., профессор, г. н. с., руководитель отдела нейропсихофармакологии, заведующий лабораторией фармакологии психических заболеваний</p><p>Москва</p></bio><bio xml:lang="en"><p>Tatiana A. Voronina, PhD, Dr. Sci. (Med.), professor, Chief Scientific Officer, Head of the Department of Neuropsychopharmacology, Head of the Laboratory of Pharmacology of Mental Diseases</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «ФИЦ оригинальных и перспективных биомедицинских и фармацевтических технологий»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal research center for innovator and emerging biomedical and pharmaceutical technologies</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>08</day><month>08</month><year>2024</year></pub-date><volume>0</volume><issue>2</issue><fpage>50</fpage><lpage>56</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Бояркин В.С., Капица И.Г., Воронина Т.А., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Бояркин В.С., Капица И.Г., Воронина Т.А.</copyright-holder><copyright-holder xml:lang="en">Boyarkin V.S., Kapitsa I.G., Voronina T.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmacokinetica.ru/jour/article/view/419">https://www.pharmacokinetica.ru/jour/article/view/419</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. Расстройства аутистического спектра (РАС) — нарушение развития мозга с неясной этиологией и патофизиологией, характеризующееся нарушением социального общения, стереотипным или повторяющимся поведением и умственной отсталостью разной степени. Одним из факторов окружающей среды, оказывающих неблагоприятное влияние на беременных женщин и на развитие эмбриона, является пропионовая кислота (ППК), которая является вторичным метаболитом кишечной микробиоты и широко используется в качестве пищевого консерванта. В физиологических условиях ППК модулирует клеточную передачу сигнала, синтез и высвобождение нейротрансмиттеров, клеточное взаимодействие, экспрессию генов, иммунную функцию, влияет на митохондриальный и липидный метаболизм. Чрезмерное воздействие ППК может оказывать ряд негативных последствий на здоровье и поведение, в том числе приводить к развитию РАС.</p><p>Целью настоящей работы была оценка поведенческих особенностей у самцов и самок крыс Вистар с РАС, вызванным пренатальным введением натриевой соли пропионовой кислоты, на стадии раннего перинатального и ювенильного периода развития.</p></sec><sec><title>Методы</title><p>Методы. В условиях модели РАС, индуцированной пренатальным введением пропионовой кислоты в дозе 500 мг/кг, п/к на 12–16 дни гестации, проведена оценка поведения в «гнездовой» и ювенильный периоды жизни самцов и самок крыс Вистар. Оценивали физическое и неврологическое развитие, социальное поведение («Материнский запах», «Парный тест»), повторяющееся поведение (Y-лабиринт, «Автогруминг»), двигательную и исследовательскую активность («Норковый тест»).</p></sec><sec><title>Результаты</title><p>Результаты. У крыс Вистар, пренатально получавших пропионовую кислоту, отмечалось замедление формирования ряда рефлексов на стадии раннего постнатального развития, а в более поздние сроки — снижение социального поведения, усиление стереотипии и агрессии, гиперлокомоция и низкая исследовательская активность.</p></sec><sec><title>Заключение</title><p>Заключение. Модель РАС, индуцированная пренатальным введением ППК, является адекватной и пригодной для изучения средств фармакологической коррекции РАС.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Relevance</title><p>Relevance. Autism spectrum disorder (ASD) is a developmental disorder of the brain with unclear etiology and pathophysiology, characterized by impaired social communication, stereotypic or repetitive behavior, and varying degrees of mental retardation. One of the environmental factors that have an adverse effect on pregnant women and embryo development is propionic acid (PPA), which is a secondary metabolite of the intestinal microbiota and is widely used as a food preservative. Under physiological conditions, PPC modulates cellular signal transduction, neurotransmitter synthesis and release, cellular interactions, gene expression, immune function, and affects mitochondrial and lipid metabolism. Excessive exposure to PPC can have a number of negative consequences on health and behavior, including leading to the development of ASD.</p><p>The aim of present research was to assess behavioral characteristics in male and female Wistar rats with ASD caused by prenatal administration of sodium salt of propionic acid at the early perinatal and juvenile stages of development.</p></sec><sec><title>Methods</title><p>Methods. In a model of ASD induced by prenatal administration of propionic acid at a dose of 500 mg/kg, subcutaneously on days 12–16 of gestation, behavior was assessed in the “nesting” and juvenile periods of life in male and female Wistar rats. Physical and neurological development, social behavior (“Maternal scent”, “Paired test”), repetitive behavior (Y-maze, “Auto-grooming”), motor and exploratory activity (“Mink test”) were assessed.</p></sec><sec><title>Results</title><p>Results. In Wistar rats prenatally treated with propionic acid, there was a slowdown in the formation of a number of reflexes at the stage of early postnatal development, and at a later stage – a decrease in social behavior, increased stereotypy and aggression, hyperlocomotion and low exploratory activity.</p></sec><sec><title>Conclusion</title><p>Conclusion. The ASD model induced by prenatal administration of PPC is adequate and suitable for studying means of pharmacological correction of ASD.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>расстройство аутистического спектра</kwd><kwd>пренатальное введение пропионовой кислоты</kwd><kwd>крысы</kwd><kwd>ранний перинатальный «гнездовой» период</kwd><kwd>ювенильный период</kwd><kwd>поведение</kwd></kwd-group><kwd-group xml:lang="en"><kwd>autism spectrum disorder</kwd><kwd>prenatal administration of propionic acid</kwd><kwd>rats</kwd><kwd>early perinatal nesting period</kwd><kwd>juvenile period</kwd><kwd>behavior</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Mehan S., Rahi S., Tiwari A., et al. Adenylate cyclase activator forskolin alleviates intracerebroventricular propionic acid-induced mitochondrial dysfunction of autistic rats. Neural Regen Res. 2020;15(6):1140-1149. doi: 10.4103/1673-5374.270316.</mixed-citation><mixed-citation xml:lang="en">Mehan S., Rahi S., Tiwari A., et al. Adenylate cyclase activator forskolin alleviates intracerebroventricular propionic acid-induced mitochondrial dysfunction of autistic rats. Neural Regen Res. 2020;15(6):1140-1149. doi: 10.4103/1673-5374.270316.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Foley K.A., Ossenkopp K.P., Kavaliers M., Macfabe D.F. Pre- and neonatal exposure to lipopolysaccharide or the enteric metabolite, propionic acid, alters development and behavior in adolescent rats in a sexually dimorphic manner. PLoS One. 2014;9(1):e87072. doi: 10.1371/journal.pone.0087072.</mixed-citation><mixed-citation xml:lang="en">Foley K.A., Ossenkopp K.P., Kavaliers M., Macfabe D.F. Pre- and neonatal exposure to lipopolysaccharide or the enteric metabolite, propionic acid, alters development and behavior in adolescent rats in a sexually dimorphic manner. PLoS One. 2014;9(1):e87072. doi: 10.1371/journal.pone.0087072.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Sharma A.R., Batra G., Saini L., et al. Valproic acid and propionic acid modulated mechanical pathways associated with autism spectrum disorder at prenatal and neonatal exposure. CNS Neurol Disord Drug Targets. 2022;21(5):399-408. doi: 10.2174/1871527320666210806165430.</mixed-citation><mixed-citation xml:lang="en">Sharma A.R., Batra G., Saini L., et al. Valproic acid and propionic acid modulated mechanical pathways associated with autism spectrum disorder at prenatal and neonatal exposure. CNS Neurol Disord Drug Targets. 2022;21(5):399-408. doi: 10.2174/1871527320666210806165430.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Vuong H.E., Hsiao E.Y. Emerging roles for the gut microbiome in autism spectrum disorder. Biological Psychiatry. 2017;81(5):411-423. doi: 10.1016/j.biopsych.2016.08.024.</mixed-citation><mixed-citation xml:lang="en">Vuong H.E., Hsiao E.Y. Emerging roles for the gut microbiome in autism spectrum disorder. Biological Psychiatry. 2017;81(5):411-423. doi: 10.1016/j.biopsych.2016.08.024.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Kwak M., Kim S.H., Kim H.H., et al. Psychobiotics and fecal microbial transplantation for autism and attention-deficit/hyperactivity disorder: microbiome modulation and therapeutic mechanisms. Front Cell Infect Microbiol. 2023;13. doi: 10.3389/fcimb.2023.1238005.</mixed-citation><mixed-citation xml:lang="en">Kwak M., Kim S.H., Kim H.H., et al. Psychobiotics and fecal microbial transplantation for autism and attention-deficit/hyperactivity disorder: microbiome modulation and therapeutic mechanisms. Front Cell Infect Microbiol. 2023;13. doi: 10.3389/fcimb.2023.1238005.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Hu T., Dong Y., He C., et al. The gut microbiota and oxidative stress in autism spectrum disorders (ASD). Oxid Med Cell Longev. 2020;2020:8396708. doi: 10.1155/2020/8396708.</mixed-citation><mixed-citation xml:lang="en">Hu T., Dong Y., He C., et al. The gut microbiota and oxidative stress in autism spectrum disorders (ASD). Oxid Med Cell Longev. 2020;2020:8396708. doi: 10.1155/2020/8396708.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Mepham J.R., MacFabe D.F., Boon F.H., et al. Examining the non-spatial pretraining effect on a water maze spatial learning task in rats treated with multiple intracerebroventricular (ICV) infusions of propionic acid: Contributions to a rodent model of ASD. Behav Brain Res. 2021; 403:113140. doi: 10.1016/j.bbr.2021.113140.</mixed-citation><mixed-citation xml:lang="en">Mepham J.R., MacFabe D.F., Boon F.H., et al. Examining the non-spatial pretraining effect on a water maze spatial learning task in rats treated with multiple intracerebroventricular (ICV) infusions of propionic acid: Contributions to a rodent model of ASD. Behav Brain Res. 2021; 403:113140. doi: 10.1016/j.bbr.2021.113140.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Wang L., Christophersen C.T., Sorich M.J., et al. Elevated fecal short chain fatty acid and ammonia concentrations in children with autism spectrum disorder. Dig Dis Sci. 2012;57(8):2096-2102. doi: 10.1007/s10620-012-2167-7.</mixed-citation><mixed-citation xml:lang="en">Wang L., Christophersen C.T., Sorich M.J., et al. Elevated fecal short chain fatty acid and ammonia concentrations in children with autism spectrum disorder. Dig Dis Sci. 2012;57(8):2096-2102. doi: 10.1007/s10620-012-2167-7.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Abdelli L.S., Samsam A., Naser S.A. Propionic acid induces gliosis and neuro-inflammation through modulation of PTEN/AKT pathway in autism spectrum disorder. Sci Rep. 2019;9(1):8824. doi: 10.1038/s41598-019-45348-z</mixed-citation><mixed-citation xml:lang="en">Abdelli L.S., Samsam A., Naser S.A. Propionic acid induces gliosis and neuro-inflammation through modulation of PTEN/AKT pathway in autism spectrum disorder. Sci Rep. 2019;9(1):8824. doi: 10.1038/s41598-019-45348-z</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">MacFabe D.F., Cain D.P., Rodriguez-Capote K., et al. Neurobiological effects of intraventricular propionic acid in rats: possible role of short chain fatty acids on the pathogenesis and characteristics of autism spectrum disorders. Behav Brain Res. 2007;176(1):149-169. doi: 10.1016/j.bbr.2006.07.025.</mixed-citation><mixed-citation xml:lang="en">MacFabe D.F., Cain D.P., Rodriguez-Capote K., et al. Neurobiological effects of intraventricular propionic acid in rats: possible role of short chain fatty acids on the pathogenesis and characteristics of autism spectrum disorders. Behav Brain Res. 2007;176(1):149-169. doi: 10.1016/j.bbr.2006.07.025.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Meeking M.M., MacFabe D.F., Mepham J.R., et al. Propionic acid induced behavioural effects of relevance to autism spectrum disorder evaluated in the hole board test with rats. Prog Neuro-Psychopharmacol Biol Psychiatry. 2020;97:109794. doi: 10.1016/j.pnpbp.2019.109794.</mixed-citation><mixed-citation xml:lang="en">Meeking M.M., MacFabe D.F., Mepham J.R., et al. Propionic acid induced behavioural effects of relevance to autism spectrum disorder evaluated in the hole board test with rats. Prog Neuro-Psychopharmacol Biol Psychiatry. 2020;97:109794. doi: 10.1016/j.pnpbp.2019.109794.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Choi J., Lee S., Won J., et al. Pathophysiological and neurobehavioral characteristics of a propionic acid-mediated autism-like rat model. PLoS One. 2018;13(2):e0192925. doi: 10.1371/journal.pone.0192925.</mixed-citation><mixed-citation xml:lang="en">Choi J., Lee S., Won J., et al. Pathophysiological and neurobehavioral characteristics of a propionic acid-mediated autism-like rat model. PLoS One. 2018;13(2):e0192925. doi: 10.1371/journal.pone.0192925.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">González-Cano S.I., Camacho-Abrego I., Diaz A., et al. Prenatal exposure to propionic acid induces altered locomotion and reactive astrogliosis in male rats. J Chem Neuroanat. 2021:117:102011. doi: 10.1016/j.jchemneu.2021.102011.</mixed-citation><mixed-citation xml:lang="en">González-Cano S.I., Camacho-Abrego I., Diaz A., et al. Prenatal exposure to propionic acid induces altered locomotion and reactive astrogliosis in male rats. J Chem Neuroanat. 2021:117:102011. doi: 10.1016/j.jchemneu.2021.102011.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Foley K.A., MacFabe D.F., Kavaliers M., Ossenkopp K.P. Sexually dimorphic effects of prenatal exposure to lipopolysaccharide, and prenatal and postnatal exposure to propionic acid, on acoustic startle response and prepulse inhibition in adolescent rats: Relevance to autism spectrum disorders. Behav Brain Res. 2015;278:244-256. doi: 10.1016/j.bbr.2014.09.032.</mixed-citation><mixed-citation xml:lang="en">Foley K.A., MacFabe D.F., Kavaliers M., Ossenkopp K.P. Sexually dimorphic effects of prenatal exposure to lipopolysaccharide, and prenatal and postnatal exposure to propionic acid, on acoustic startle response and prepulse inhibition in adolescent rats: Relevance to autism spectrum disorders. Behav Brain Res. 2015;278:244-256. doi: 10.1016/j.bbr.2014.09.032.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Малышев А.В., Разумкина Е.В., Рогозинская Э.Я. и др. Поведение и функциональное состояние дофаминергической системы мозга у детенышей депрессивных крыс линии WAG/RIJ. Журнал высшей нервной деятельности им. И.П. Павлова. 2014;64(3):334-346. doi: 10.7868/S0044467714030101.</mixed-citation><mixed-citation xml:lang="en">Malyshev A.V., Razumkina E.V., Rogozinskaia E.Y., et al. Behavior and Functional State of the Dopaminergic Brain System in Pups of Depressive WAG/Rij Rats. Zh Vyssh Nerv Deiat Im I. P. Pavlova. 2014;64(3):334-46. (In Russ). doi: 10.7868/S0044467714030101.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Mirza R., Sharma B. Selective modulator of peroxisome proliferator- activated receptor-α protects propionic acid induced autism-like phenotypes in rats. Life Sci. 2018;214:106-117. doi: 10.1016/j.lfs.2018.10.045.</mixed-citation><mixed-citation xml:lang="en">Mirza R., Sharma B. Selective modulator of peroxisome proliferator- activated receptor-α protects propionic acid induced autism-like phenotypes in rats. Life Sci. 2018;214:106-117. doi: 10.1016/j.lfs.2018.10.045.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Daghestani M.H., Selim M.E., Abd-Elhakim Y.M., et al. The role of apitoxin in alleviating propionic acid-induced neurobehavioral impairments in rat pups: The expression pattern of Reelin gene. Biomed Pharmacother. 2017;93:48-56. doi: 10.1016/j.biopha.2017.06.034.</mixed-citation><mixed-citation xml:lang="en">Daghestani M.H., Selim M.E., Abd-Elhakim Y.M., et al. The role of apitoxin in alleviating propionic acid-induced neurobehavioral impairments in rat pups: The expression pattern of Reelin gene. Biomed Pharmacother. 2017;93:48-56. doi: 10.1016/j.biopha.2017.06.034.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Shams S., Foley K.A., Kavaliers M., et al. Systemic treatment with the enteric bacterial metabolic product propionic acid results in reduction of social behavior in juvenile rats: Contribution to a rodent model of autism spectrum disorder. Dev Psychobiol. 2019;61(5):688-699. doi: 10.1002/dev.21825.</mixed-citation><mixed-citation xml:lang="en">Shams S., Foley K.A., Kavaliers M., et al. Systemic treatment with the enteric bacterial metabolic product propionic acid results in reduction of social behavior in juvenile rats: Contribution to a rodent model of autism spectrum disorder. Dev Psychobiol. 2019;61(5):688-699. doi: 10.1002/dev.21825.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao F. Zhang H., Wang P., et al. Oxytocin and serotonin in the modulation of neural function: Neurobiological underpinnings of autism- related behavior. Front Neurosci. 2022;16: 919890. doi: 10.3389/fnins.2022.919890.</mixed-citation><mixed-citation xml:lang="en">Zhao F. Zhang H., Wang P., et al. Oxytocin and serotonin in the modulation of neural function: Neurobiological underpinnings of autism- related behavior. Front Neurosci. 2022;16: 919890. doi: 10.3389/fnins.2022.919890.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Paudel R., Raj K., Gupta Y.K., et al. Oxiracetam and zinc ameliorates autism-like symptoms in propionic acid model of rats. Neurotox Res. 2020;37(4):815-826. doi: 10.1007/s12640-020-00169-1.</mixed-citation><mixed-citation xml:lang="en">Paudel R., Raj K., Gupta Y.K., et al. Oxiracetam and zinc ameliorates autism-like symptoms in propionic acid model of rats. Neurotox Res. 2020;37(4):815-826. doi: 10.1007/s12640-020-00169-1.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Mandic-Maravic V., Grujicic R., Milutinovic L., et al. Dopamine in autism spectrum disorders – focus on D2/D3 partial agonists and their possible use in treatment. Front Psychiatry. 2022;12:787097. doi: 10.3389/fpsyt.2021.787097.</mixed-citation><mixed-citation xml:lang="en">Mandic-Maravic V., Grujicic R., Milutinovic L., et al. Dopamine in autism spectrum disorders – focus on D2/D3 partial agonists and their possible use in treatment. Front Psychiatry. 2022;12:787097. doi: 10.3389/fpsyt.2021.787097.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
